Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct 30;10(21):e39705.
doi: 10.1016/j.heliyon.2024.e39705. eCollection 2024 Nov 15.

Late-onset tacrolimus-induced encephalopathy in lung transplant recipient: Case report

Affiliations
Case Reports

Late-onset tacrolimus-induced encephalopathy in lung transplant recipient: Case report

Qiaoyan Lian et al. Heliyon. .

Abstract

Background: Tacrolimus is regarded as a cornerstone of immunosuppressive therapy after lung transplantation. Tacrolimus-induced neurotoxicity is common, while late-onset severe encephalopathy is rare.

Case presentation: We report a case of a 61-year-old woman who presented with confusion and limb stiffness 29 months after undergoing bilateral lung transplantation for bronchiectasis. She received immunosuppressive regimen consisting of low-dose tacrolimus, sirolimus, mycophenolate mofetil, and prednisone due to renal insufficiency. Neurological examination revealed gaze deviation towards the right side in both eyes, as well as nuchal rigidity. The muscle strength of her extremities was at grade 1-2, and muscle tone was increased, with a bilateral positive Babinski sign. Blood tests revealed that tacrolimus and sirolimus levels were within the therapeutic range. Brain magnetic resonance imaging revealed that periventricular white matter lesions were slightly more extensive than those observed prior to transplantation. Lumbar puncture showed that cerebrospinal fluid pressure and composition were normal. A diagnosis of tacrolimus-induced encephalopathy was made after a thorough clinical examination. Subsequently, cyclosporine was administered instead of tacrolimus for anti-rejection therapy, and she has remained free of neurological symptoms since then. The improvement of clinical symptoms following the withdrawal of tacrolimus supports the drug-induced etiology of this neurological disorder.

Conclusions: We highlight that tacrolimus-induced encephalopathy can occur in a late stage after lung transplantation and may occur with tacrolimus whole blood concentrations within the therapeutic range.

Keywords: Case report; Encephalopathy; Lung transplant; Tacrolimus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Brain MRI manifestations of the present patient. (A) T2-weighted image shows small patchy abnormal signals in the white matter around the bilateral ventricles before lung transplantation. (B) At the time the patient appeared to have personality changes, MRI revealed periventricular white matter lesions mildly more extensive than before lung transplantation. (C) When the patient's condition rapidly worsened with confusion, MRI showed periventricular white matter lesions almost identical to those observed in (B).
Fig. 2
Fig. 2
Whole blood trough concentrations of immunosuppressive agents and neurological symptoms of the present patient. Red: with neurological symptoms (irritability, confusion, and limb stiffness); Green: without neurological symptoms.

Similar articles

References

    1. Braithwaite H.E., Darley D.R., Brett J., et al. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: a systematic review. Transplant. Rev. 2021;35(2) - PubMed
    1. Mammoser A. Calcineurin inhibitor encephalopathy. Semin. Neurol. 2012;32(5):517–524. - PubMed
    1. Zhang W., Egashira N., Masuda S. Recent topics on the mechanisms of immunosuppressive therapy-related neurotoxicities. Int. J. Mol. Sci. 2019;20(13) - PMC - PubMed
    1. Wu Q., Marescaux C., Wolff V., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur. Neurol. 2010;64(3):169–177. - PubMed
    1. Frühauf N.R., Koeppen Dagger S., Saner F.H., et al. Late onset of tacrolimus-related posterior leukoencephalopathy after living donor liver transplantation. Liver Transplant. 2003;9(9):983–985. - PubMed

Publication types

LinkOut - more resources